MYC and Miyoshi myopathy: Having in mind the impending negative effects of the available hematopoietic treatments and given that c-MYC dysregulation is a distinct feature in the genetic profile of MM, alternative approaches were forged to identify novel drugs targeting c-MYC, especially because such therapies are not yet available [11,12].